

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/22/2003	Robert John Speirs	17968.008	7674
90 04/05/2005		EXAM	INER
ration		SACKEY, EE	BENEZER O
perty - R440		ART UNIT	PAPER NUMBER
94662-8097		1626	
	90 04/05/2005 ation	90 04/05/2005 ation perty - R440	90 04/05/2005 EXAM ation SACKEY, EE perty - R440 ART UNIT

DATE MAILED: 04/05/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
Somple mental	10/743,529	SPEIRS ET AL.		
Notice of Allowability	Examiner	Art Unit		
	EBENEZER SACKEY	1626		
The MAILING DATE of this communication app. All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap) or other appropriate communication (IGHTS. This application is subject to 3 and MPEP 1308.	oplication. If not included n will be mailed in due course. THIS		
2. The allowed claim(s) is/are claims 29-34, now claims 1-6 p	respectively.			
3. The drawings filed on are accepted by the Examine	er.			
4. ☐ Acknowledgment is made of a claim for foreign priority una) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. ☐ A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must (a) ☐ including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner' Paper No./Mail Date Identifying Indicia such as the application number (see 37 CFR 1)	e been received. e been received in Application No cuments have been received in this of this communication to file a reply MENT of this application. inted. Note the attached EXAMINER es reason(s) why the oath or declara est be submitted. son's Patent Drawing Review (PTO- c. s Amendment / Comment or in the Comme	national stage application from the complying with the requirements SS AMENDMENT or NOTICE OF ation is deficient. 948) attached Office action of		
each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.				
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 06/28/04 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Da 08), 7. ☑ Examiner's Amendr	Patent Application (PTO-152) (PTO-413), te ment/Comment ent of Reasons for Allowance		
U.S. Patent and Trademark Office				



EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Dennis K. Shelton on 03/02/05.

The application has been amended as follows:

IN THE SPECIFICATION

On page 66, lines 9-11, delete the following:

Figures 1 through 20 graphically illustrate serum tobramycin concentrations before and after period 1 and period 2 dosing for all individual subjects.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to E. Sackey whose telephone number is (571) 272-0704. The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane, can be reached on (571) 272-0699. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600. EOS

Art Unit: 1626

March 3, 2005

Joseph K. M. Karf Joseph K. McKane

Supervisory Patent Examiner
Art Unit 1626, Group 1600
Technology Center 1

Page 3